Pediatric ganglioglioma of the brainstem and cervicomedullary junction: a retrospective cohort study

View More View Less
  • 1 Departments of Neurologic Surgery and
  • 2 Pathology, Mayo Clinic, Rochester, Minnesota
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

OBJECTIVE

Ganglioglioma is a low-grade central nervous system neoplasm with a pediatric predominance, accounting for 10% of all brain tumors in children. Gangliogliomas of the cervicomedullary junction (GGCMJs) and brainstem (GGBSs) present a host of management challenges, including a significant risk of surgical morbidity. At present, understanding of the prognostic factors—including BRAF V600E status—is incomplete. Here, the authors report a single-institution GGCMJ and GGBS experience and review the pertinent literature.

METHODS

A prospectively maintained neurosurgical database at a large tertiary care academic referral center was retrospectively queried for cases of GGCMJ pathologically confirmed in the period from 1995 to 2015; appropriate cases were defined by diagnosis codes and keywords. Secondary supplemental chart review was conducted to confirm or capture relevant data. The primary study outcome was treatment failure as defined by evidence of radiographic recurrence or progression and/or clinical or functional decline. A review of the literature was conducted as well.

RESULTS

Five neurosurgically managed GGBS patients were identified, and the neoplasms in 4 were classified as GGCMJ. All 5 patients were younger than 18 years old (median 15 years, range 4–16 years) and 3 (60%) were female. One patient underwent gross-total resection, 2 underwent aggressive subtotal resection (STR), and 2 underwent stereotactic biopsy only. All patients who had undergone STR or biopsy required repeat resection for tumor control or progression. Progressive disease was treated with radiotherapy in 2 patients, chemotherapy in 2, and chemoradiotherapy alone in 1. Immunostaining for BRAF V600E was positive in 3 patients (60%). All 5 patients experienced at least one major complication, including wound infection, foot drop, hemiparesis, quadriparesis, cranial neuropathy, C2–3 subluxation, syringomyelia, hydrocephalus, aspiration, and coma. Overall mortality was 20%, with 1 death observed over 11 years of follow-up.

CONCLUSIONS

GGBS and GGCMJ are rare, benign posterior fossa tumors that carry significant perioperative morbidity. Contemporary management strategies are heterogeneous and include combinations of resection, radiotherapy, and chemotherapy. The BRAF V600E mutation is frequently observed in GGBS and GGCMJ and appears to have both prognostic and therapeutic significance with targeted biological agents.

ABBREVIATIONS CNS = central nervous system; EOR = extent of resection; GGBS = ganglioglioma of the brainstem; GGCMJ = ganglioglioma of the cervicomedullary junction; GTR = gross-total resection; STR = subtotal resection.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Correspondence David J. Daniels: Mayo Clinic, Rochester, MN. daniels.david@mayo.edu.

INCLUDE WHEN CITING Published online October 4, 2019; DOI: 10.3171/2019.7.PEDS1961.

Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

  • 1

    Adachi Y, Yagishita A: Gangliogliomas: Characteristic imaging findings and role in the temporal lobe epilepsy. Neuroradiology 50:829834, 2008

    • Search Google Scholar
    • Export Citation
  • 2

    Aguilera D, Janss A, Mazewski C, Castellino RC, Schniederjan M, Hayes L, : Successful retreatment of a child with a refractory brainstem ganglioglioma with vemurafenib. Pediatr Blood Cancer 63:541543, 2016

    • Search Google Scholar
    • Export Citation
  • 3

    Baussard B, Di Rocco F, Garnett MR, Boddaert N, Lellouch-Tubiana A, Grill J, : Pediatric infratentorial gangliogliomas: a retrospective series. J Neurosurg 107 (4 Suppl):286291, 2007

    • Search Google Scholar
    • Export Citation
  • 4

    Blatt GL, Ahuja A, Miller LL, Ostrow PT, Soloniuk DS: Cerebellomedullary ganglioglioma: CT and MR findings. AJNR Am J Neuroradiol 16:790792, 1995

    • Search Google Scholar
    • Export Citation
  • 5

    Blümcke I, Wiestler OD: Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol 61:575584, 2002

    • Search Google Scholar
    • Export Citation
  • 6

    Castillo M, Davis PC, Takei Y, Hoffman JC Jr: Intracranial ganglioglioma: MR, CT, and clinical findings in 18 patients. AJR Am J Roentgenol 154:607612, 1990

    • Search Google Scholar
    • Export Citation
  • 7

    Chappé C, Padovani L, Scavarda D, Forest F, Nanni-Metellus I, Loundou A, : Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAFV600E mutation and expression. Brain Pathol 23:574583, 2013

    • Search Google Scholar
    • Export Citation
  • 8

    Chen X, Pan C, Zhang P, Xu C, Sun Y, Yu H, : BRAF V600E mutation is a significant prognosticator of the tumour regrowth rate in brainstem gangliogliomas. J Clin Neurosci 46:5057, 2017

    • Search Google Scholar
    • Export Citation
  • 9

    Chintagumpala MM, Armstrong D, Miki S, Nelson T, Cheek W, Laurent J, : Mixed neuronal-glial tumors (gangliogliomas) in children. Pediatr Neurosurg 24:306313, 1996

    • Search Google Scholar
    • Export Citation
  • 10

    Compton JJ, Laack NN, Eckel LJ, Schomas DA, Giannini C, Meyer FB: Long-term outcomes for low-grade intracranial ganglioglioma: 30-year experience from the Mayo Clinic. J Neurosurg 117:825830, 2012

    • Search Google Scholar
    • Export Citation
  • 11

    Dahiya S, Haydon DH, Alvarado D, Gurnett CA, Gutmann DH, Leonard JR: BRAFV600E mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol 125:901910, 2013

    • Search Google Scholar
    • Export Citation
  • 12

    Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, : Mutations of the BRAF gene in human cancer. Nature 417:949954, 2002

  • 13

    del Bufalo F, Carai A, Figà-Talamanca L, Pettorini B, Mallucci C, Giangaspero F, : Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent. J Transl Med 12:356, 2014

    • Search Google Scholar
    • Export Citation
  • 14

    Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, : Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 12:621630, 2010

    • Search Google Scholar
    • Export Citation
  • 15

    Dudley RW, Torok MR, Gallegos DR, Mulcahy-Levy JM, Hoffman LM, Liu AK, : Pediatric low-grade ganglioglioma: epidemiology, treatments, and outcome analysis on 348 children from the surveillance, epidemiology, and end results database. Neurosurgery 76:313320, 2015

    • Search Google Scholar
    • Export Citation
  • 16

    El Khashab M, Gargan L, Margraf L, Koral K, Nejat F, Swift D, : Predictors of tumor progression among children with gangliogliomas. Clinical article. J Neurosurg Pediatr 3:461466, 2009

    • Search Google Scholar
    • Export Citation
  • 17

    Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, : Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809819, 2010

    • Search Google Scholar
    • Export Citation
  • 18

    Hashimoto M, Fujimoto K, Shinoda S, Masuzawa T: Magnetic resonance imaging of ganglion cell tumours. Neuroradiology 35:181184, 1993

  • 19

    Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, : Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358365, 2012

    • Search Google Scholar
    • Export Citation
  • 20

    Im SH, Chung CK, Cho BK, Lee SK: Supratentorial ganglioglioma and epilepsy: postoperative seizure outcome. J Neurooncol 57:5966, 2002

    • Search Google Scholar
    • Export Citation
  • 21

    Janjua MB, Ivasyk I, Pisapia DJ, Souweidane MM: Ganglioglioma of brain stem and cervicomedullary junction: a 50 years review of literature. J Clin Neurosci 44:3446, 2017

    • Search Google Scholar
    • Export Citation
  • 22

    Johnson JH Jr, Hariharan S, Berman J, Sutton LN, Rorke LB, Molloy P, : Clinical outcome of pediatric gangliogliomas: ninety-nine cases over 20 years. Pediatr Neurosurg 27:203207, 1997

    • Search Google Scholar
    • Export Citation
  • 23

    Kim SD, Kim JH, Lee CY, Kim HW: Ganglioglioma in brainstem: case report and a review of literatures. J Korean Neurosurg Soc 55:164166, 2014

    • Search Google Scholar
    • Export Citation
  • 24

    Koelsche C, Wöhrer A, Jeibmann A, Schittenhelm J, Schindler G, Preusser M, : Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 125:891900, 2013

    • Search Google Scholar
    • Export Citation
  • 25

    Lang FF, Epstein FJ, Ransohoff J, Allen JC, Wisoff J, Abbott IR, : Central nervous system gangliogliomas. Part 2: Clinical outcome. J Neurosurg 79:867873, 1993

    • Search Google Scholar
    • Export Citation
  • 26

    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, : The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97109, 2007

    • Search Google Scholar
    • Export Citation
  • 27

    Luyken C, Blümcke I, Fimmers R, Urbach H, Wiestler OD, Schramm J: Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer 101:146155, 2004

    • Search Google Scholar
    • Export Citation
  • 28

    McAbee JH, Modica J, Thompson CJ, Broniscer A, Orr B, Choudhri AF, : Cervicomedullary tumors in children. J Neurosurg Pediatr 16:357366, 2015

    • Search Google Scholar
    • Export Citation
  • 29

    McKay MM, Morrison DK: Integrating signals from RTKs to ERK/MAPK. Oncogene 26:31133121, 2007

  • 30

    Mickle JP: Ganglioglioma in children. A review of 32 cases at the University of Florida. Pediatr Neurosurg 18:310314, 1992

  • 31

    Milligan BD, Giannini C, Link MJ: Ganglioglioma in the cerebellopontine angle in a child. Case report and review of the literature. J Neurosurg 107 (4 Suppl):292296, 2007

    • Search Google Scholar
    • Export Citation
  • 32

    Morice C, Nothias F, König S, Vernier P, Baccarini M, Vincent JD, : Raf-1 and B-Raf proteins have similar regional distributions but differential subcellular localization in adult rat brain. Eur J Neurosci 11:19952006, 1999

    • Search Google Scholar
    • Export Citation
  • 33

    Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, : Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res 17:75957604, 2011

    • Search Google Scholar
    • Export Citation
  • 34

    Pan CC, Chen X, Xu C, Wu WH, Zhang P, Wang Y, : Brainstem gangliogliomas: prognostic factors, surgical indications and functional outcomes. J Neurooncol 128:445453, 2016

    • Search Google Scholar
    • Export Citation
  • 35

    Rumana CS, Valadka AB: Radiation therapy and malignant degeneration of benign supratentorial gangliogliomas. Neurosurgery 42:10381043, 1998

    • Search Google Scholar
    • Export Citation
  • 36

    Rush S, Foreman N, Liu A: Brainstem ganglioglioma successfully treated with vemurafenib. J Clin Oncol 31:e159e160, 2013

  • 37

    Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, : Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397405, 2011

    • Search Google Scholar
    • Export Citation
  • 38

    Sebolt-Leopold JS, Herrera R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4:937947, 2004

  • 39

    Shih KC, Shastry M, Williams JT, Jelsma PF, Abram SR, Ayyanar K, : Successful treatment with dabrafenib (GSK2118436) in a patient with ganglioglioma. J Clin Oncol 32:e98e100, 2014

    • Search Google Scholar
    • Export Citation
  • 40

    Sutton LN, Packer RJ, Rorke LB, Bruce DA, Schut L: Cerebral gangliogliomas during childhood. Neurosurgery 13:124128, 1983

  • 41

    Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, : Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105:30413046, 2008

    • Search Google Scholar
    • Export Citation
  • 42

    Wellbrock C, Karasarides M, Marais R: The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5:875885, 2004

  • 43

    Zentner J, Wolf HK, Ostertun B, Hufnagel A, Campos MG, Solymosi L, : Gangliogliomas: clinical, radiological, and histopathological findings in 51 patients. J Neurol Neurosurg Psychiatry 57:14971502, 1994

    • Search Google Scholar
    • Export Citation
  • 44

    Zhang D, Henning TD, Zou LG, Hu LB, Wen L, Feng XY, : Intracranial ganglioglioma: clinicopathological and MRI findings in 16 patients. Clin Radiol 63:8091, 2008

    • Search Google Scholar
    • Export Citation
  • 45

    Zhang S, Wang X, Liu X, Ju Y, Hui X: Brainstem gangliogliomas: a retrospective series. J Neurosurg 118:884888, 2013

Metrics